Less May Be More When Treating Newly Diagnosed AML
Neither a higher dose of daunorubicin nor a second induction cycle improved outcomes in fit patients with newly diagnosed acute myeloid leukemia.
Neither a higher dose of daunorubicin nor a second induction cycle improved outcomes in fit patients with newly diagnosed acute myeloid leukemia.
Combination magrolimab, azacitidine, and venetoclax appears effective in patients with newly diagnosed acute myeloid leukemia.
Pivekimab sunirine plus azacitidine and venetoclax has demonstrated activity in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia.
The FDA has approved Rezlidhia (olutasidenib) to treat patients with IDH1-mutated, relapsed or refractory acute myeloid leukemia.
Adding gilteritinib to azacitidine did not improve survival outcomes in patients with newly diagnosed, FLT3-mutated acute myeloid leukemia.
Young adult survivors of pediatric cancer experience significant premature aging, a retrospective study suggests.
Oral azacitidine improved survival independent of NPM1 or FLT3 mutational status, cytogenetic risk, or MRD status after chemotherapy.
Among AYAs with AML, Black patients experience higher rates of early death and lower rates of overall survival than White patients.
FLT3-ITD minimal residual disease is associated with an increased risk of relapse and death in patients with acute myeloid leukemia.
Researchers sought to determine outcomes in patients with MDS whose disease progressed during treatment with hypomethylating agents.